Plain Language Summary {#Sec1}
======================

Angina is a condition that affects more than 100 million patients worldwide. The drug ivabradine administered together with a beta-blocker has been shown to improve angina symptoms. A new formulation exists, in which ivabradine is combined in a single pill with the beta-blocker metoprolol. This study analyzed the effect of treatment with this new formulation in different groups of patients according to age, duration of disease, functional status, and presence of other health conditions. In all the patient groups analyzed, this treatment decreased the number of angina attacks and the use of nitroglycerine. It also improved functional status. Moreover, the number of patients taking their medicine as prescribed, as reported by patients themselves, increased. This new formulation could therefore provide an opportunity to improve angina symptoms and increase the number of patients following their treatment.

Introduction {#Sec2}
============

Ischemic heart disease remains the leading cause of health loss in both sexes \[[@CR1]\]. Angina pectoris (AP) due to coronary artery disease (CAD) affects approximately 112 million people in the world \[[@CR2]\].

Heart rate (HR) is one of the main determinants of myocardial oxygen consumption. Elevated HR shortens the length of each cardiac cycle and reduces diastolic perfusion time, decreasing oxygen supply. This imbalance leads to myocardial ischemia, which can trigger angina symptoms \[[@CR3]\]. In patients with stable angina, most episodes of exercise-induced myocardial ischemia are preceded by an increase in HR \[[@CR4]\]. Development of ischemia is related to baseline HR as well as to the extent and duration of HR increase \[[@CR5]\]. The frequency of ambulatory ischemic episodes in treated CAD patients is related to their mean HR, with patients with a HR of 80 beats per minute (bpm) experiencing ischemia almost twice as often as those with a HR of 70 bpm \[[@CR6]\]. There is also strong evidence supporting the association between HR and mortality in patients with stable angina \[[@CR7], [@CR8]\].

Reducing resting HR is very important when treating patients with stable angina and CAD, and the latest guidelines for the treatment of stable angina recommend reaching target levels of ≤ 60 bpm \[[@CR9]\]. Beta-blockers (BB) are currently recommended as the first-line anti-anginal treatment for reducing HR and angina symptoms \[[@CR9]\]. In the CLARIFY registry, the majority of patients (79%) with angina symptoms were treated with a BB; however, their average HR was above the target levels. Moreover, among the 7301 patients with angina symptoms, only 25% (*n* = 1818) had their HR controlled (≤ 60 bpm) \[[@CR10]\].

Combining a BB with ivabradine has been shown to further reduce the HR of patients with stable angina, along with myocardial ischemia and symptoms of angina \[[@CR11], [@CR12]\]. Ivabradine selectively inhibits the funny current (*I*~f~), which reduces HR, leading to a decrease in myocardial oxygen demand while increasing both coronary filling time and blood flow, thus protecting against ischemia and angina symptoms \[[@CR13], [@CR14]\].

In addition to treatment choice and dose, non-adherence of patients to their treatment can explain suboptimal angina control. Approximately 50% of patients with cardiovascular disease and/or its major risk factors have poor adherence to their prescribed medications \[[@CR15]\]. Non-adherence is well-described for asymptomatic conditions such as hypertension, but it has also been observed in symptomatic conditions, including in patients with angina \[[@CR16]\]. A study based on patient self-reports found that as many as 54% of CAD patients were non-adherent to treatment with BBs \[[@CR17]\]. Non-adherence to medication is a complex phenomenon affected by several factors \[[@CR18]\]. Existing experience points to the number of daily doses as an important predictor of adherence \[[@CR19]\]. Simplification of the treatment regimen, for example through the use of fixed-dose combinations (FDC), could lead to improved adherence and potential clinical benefit.

The effectiveness and safety of the first FDC formulation of metoprolol and ivabradine was assessed previously in stable AP patients in routine clinical practice \[[@CR20]\]. Herein we report an additional analysis of the data obtained in this 4-month prospective observational study, in which the effectiveness of the metoprolol/ivabradine FDC was assessed in subgroups of patients with different clinical characteristics.

Methods {#Sec3}
=======

IMPLICOR-NOW was a prospective, observational, multicenter study conducted in Germany from October 2015 to October 2016, under daily practice conditions in 260 centers \[[@CR20]\]. Stable AP patients fulfilling criteria for treatment with the new metoprolol/ivabradine FDC (Implicor™ 5/25, 5/50, 7.5/25, 7.5/50) according to the approved EU indication were eligible for inclusion. Three visits were planned: a baseline examination (visit 1), a control visit after 4 weeks (visit 2), and a final examination after 4 months (visit 3).

Demographic data and general/disease-specific medical history, information about concomitant diseases, other relevant medical therapies, and reasons for initiation of FDC treatment were recorded at the baseline visit. According to the approved label, the starting dose of the FDC should be equivalent to the dosing of the individual components (ivabradine and metoprolol) before the switch. If necessary to achieve symptom control, the dose could be adjusted during the study to a maximal dose of 7.5 mg ivabradine and 50 mg metoprolol twice daily. Dose reduction is possible in case of a pronounced HR reduction \< 50 bpm or occurrence of bradycardic symptoms during treatment.

Patient status was clinically documented at each visit by recording HR, number of weekly angina attacks, use of short-acting nitrates (SAN), and Canadian Cardiovascular Society (CCS) class. A four-item adherence questionnaire was used to assess medication adherence at baseline compared to study end after 4 months of treatment \[[@CR20]\]. "Complete adherence" was defined as the absence of any adherence-related problems reported in the questionnaire. At visit 3, physicians evaluated effectiveness and tolerability of metoprolol/ivabradine for each patient using a scale with the following categories: 'very good', 'good', 'moderate', and 'poor'.

In the present analysis, these parameters were assessed in patient subgroups specified according to age (\< 60 years, 60 to  \< 75 years, ≥ 75 years), CAD duration (\< 2 years, 2 to  \< 5 years, 5 to  \< 10 years, ≥ 10 years), CCS class (CCS class I, class II, class III and IV), history of renal dysfunction, previous percutaneous coronary intervention (PCI), previous myocardial infarction (MI), diabetes, asthma/chronic obstructive pulmonary disease (COPD), or hypertension.

Compliance with Ethics Guidelines {#Sec4}
---------------------------------

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all patients for being included in the study. Ethical approval was granted by the independent ethics commission in Freiburg/Germany (FEKI).

Statistical Analysis {#Sec5}
--------------------

Due to the observational design of the study, statistical analysis of the results was performed by a descriptive approach. Data are presented as mean values ± standard deviations (SD) for continuous variables and numbers of patients and/or percentages for categorical variables. Analysis of effectiveness data was performed with data imputation according to the last value carried forward method (LVCF). Wilcoxon's signed-rank test and Fisher's exact test were applied as appropriate for assessment of changes between baseline and follow-up visits. Corresponding *p* values should be interpreted in a descriptive-exploratory way. The *p* values reported are two-tailed and an alpha level of 0.05 was used to assess statistical significance. No correction of alpha level for multiple testing was performed. All study data were evaluated by an independent statistical institute (ANFOMED GmbH, Mohrendorf, Germany). All statistical analyses have been performed by means of the SAS software system (version 9.4 for Microsoft Windows 10; SAS Institute Inc., Cary, NC, USA).

Results {#Sec6}
=======

Data from the IMPLICOR-NOW study \[[@CR20]\] conducted in 747 patients with stable AP were used. Baseline characteristics as well as effectiveness and tolerability in the overall population were reported previously \[[@CR20]\]. Following the switch to the metoprolol/ivabradine FDC, effectiveness was assessed in patient subgroups specified according to age, CAD duration, CCS class, history of renal dysfunction, previous PCI, previous MI, diabetes, asthma/COPD, or hypertension.

In all patient subgroups, at 4 months of treatment, a significant decrease was observed in both the mean number of angina attacks and SAN consumption per week (Fig. [1](#Fig1){ref-type="fig"}). A significant decrease in HR was also consistently observed across all patient subgroups (Table [1](#Tab1){ref-type="table"}). CCS class was also significantly improved in all patient subgroups, with the proportion of CCS class I patients ranging from 11% to 35% at baseline and from 39% to 71% at month 4 (Fig. [2](#Fig2){ref-type="fig"}).Fig. 1Antianginal effectiveness after 4 months of treatment in **a** overall population, **b** age subgroups, **c** CAD duration subgroups, **d** CCS Class subgroups, and **e** medical history subgroups. Bars represent relative changes from baseline (percentages). Values shown inside bars are absolute changes from baseline (mean ± SD). \**p* \< 0.001 for all changes between baseline and month 4. *CAD* coronary artery disease, *CCS* Canadian Cardiovascular Society, *COPD* chronic obstructive pulmonary disease, *HT* hypertension, *MI* myocardial infarction, *PCI* percutaneous coronary interventionTable 1Heart rate in the different subpopulations at baseline and at 4 months*n* (%)HR at baseline (bpm)HR at M4 (bpm)Overall population747 (100.0%)76.8 ± 11.867.2 ± 8.2\*Age \< 60 years192 (25.7%)77.3 ± 12.067.6 ± 8.0\*Age 60 to \< 75 years357 (47.8%)76.4 ± 11.366.7 ± 8.1\*Age ≥ 75 years182 (24.4%)77.3 ± 12.467.9 ± 8.6\*CAD duration \< 2 years226 (30.2%)76.6 ± 11.967.5 ± 8.6\*CAD duration 2 to  \< 5 years182 (24.4%)77.5 ± 11.467.5 ± 8.4\*CAD duration 5 to  \< 10 years185 (24.8%)77.4 ± 12.066.6 ± 7.3\*CAD duration ≥ 10 years139 (18.6%)75.5 ± 11.767.2 ± 8.6\*CCS class I187 (25.0%)76.9 ± 12.067.6 ± 8.3\*CCS class II389 (52.1%)76.7 ± 11.767.0 ± 8.2\*CCS III + IV134 (17.9%)77.4 ± 11.167.5 ± 8.0\*Hypertension635 (85.0%)76.8 ± 11.867.3 ± 8.3\*Asthma/COPD141 (18.9%)78.6 ± 12.467.0 ± 8.5\*Diabetes255 (34.1%)77.0 ± 11.867.2 ± 8.2\*Previous MI230 (30.8%)74.7 ± 12.265.8 ± 8.9\*Previous PCI369 (49.4%)75.3 ± 11.865.8 ± 7.8\*Renal dysfunction65 (8.7%)77.1 ± 12.367.3 ± 8.6\*\**p* \< 0.0001 for all changes between baseline and month 4*bpm* beats per minute, *CAD* coronary artery disease, *CCS* Canadian Cardiovascular Society, *COPD* chronic obstructive pulmonary disease, *HR* heart rate, *M4* month 4, *MI* myocardial infarction, *PCI* percutaneous coronary interventionFig. 2Changes in CCS class after 4 months of treatment in **a** overall population, **b** age subgroups, **c** CAD duration subgroups and **d** medical history subgroups.*Bars* represent the proportion of patients with CCS class I, at baseline and at month 4. \**p* \< 0.001 for all changes between baseline and month 4. *CAD* coronary artery disease, *CCS* Canadian Cardiovascular Society, *COPD* chronic obstructive pulmonary disease, *HT* hypertension, *MI* myocardial infarction, *M4* month 4, *PCI* percutaneous coronary intervention

The proportion of patients with complete adherence in relation to the number of drugs used was assessed at the final visit at 4 months (*n* = 715 patients) and was found to decrease with an increasing number of medications taken by patients (Fig. [3](#Fig3){ref-type="fig"}; *p* = 0.0004 for association). In all patient subgroups, at 4 months of treatment, a significant increase in the proportion of patients with self-reported complete adherence was observed (Fig. [4](#Fig4){ref-type="fig"}).Fig. 3Complete adherence in relation to number of drugs taken at final visit (*n* = 715 patients). *p* = 0.0004Fig. 4Changes in adherence after 4 months of treatment in **a** overall population, **b** age subgroups, **c** CAD duration subgroups, **d** CCS Class subgroups, and (**e**) medical history subgroups.*Bars* represent the proportion of patients with complete adherence. \**p* \< 0.001 for all changes between baseline and month 4. *CAD* coronary artery disease, *CCS* Canadian Cardiovascular Society, *COPD* chronic obstructive pulmonary disease, *HT* hypertension, *MI* myocardial infarction, *M4* month 4, *PCI* percutaneous coronary intervention

At the last visit, the effectiveness and tolerability of the therapy was evaluated by the physicians as 'very good' or 'good' for more than 96% of patients in all analyzed subgroups (Table [2](#Tab2){ref-type="table"}).Table 2Tolerability assessment by physicians in the different subpopulations at 4 monthsPatient subgroupsTolerabilityVery good (%)Good (%)Moderate or poor (%)Age \< 60 years78.121.40.5Age 60 to \< 75 years76.621.71.7Age ≥ 75 years69.729.21.1CAD duration \< 2 years75.423.70.9CAD duration 2 to \< 5 years71.227.71.1CAD duration 5 to \< 10 years79.020.40.6CAD duration ≥ 10 years74.822.13.1CCS class I73.426.10.5CCS class II75.923.11.0CCS III + IV77.120.62.3Hypertension75.523.11.5Asthma/COPD74.623.91.4Diabetes79.119.71.2Previous MI77.022.10.9Previous PCI76.422.21.2Renal dysfunction71.427.01.6Values are expressed as proportions of patients

Adverse events (AEs) were reported in 6.70% of the patients \< 60 years old and in 5.19% of the patients 60 to 75 years old. In patients over 75 years, the proportion of patients affected by AEs was 4.35%. The proportion of patients with AEs was higher in patients with renal dysfunction (7.58%) than in patients with normal renal function (5.14%). AEs were reported in 7.75% of patients with asthma or COPD and in 4.79% of patients without asthma/COPD. Proportions of patients with AEs were similar between patients with (5.75%) and without diabetes (5.14%), between patients with (5.27%) and without hypertension (5.88%), and between patients with (5.58%) and without a MI (5.18%). In patients with CAD known for less than 2 years, AEs were reported in 6.41%. In patients with CAD duration 2 to \< 5 years, 7.49% were affected by AEs. The lowest proportion of patients with AEs was 2.70%, in the patients with duration of disease of 5 to  \< 10 years. In patients with CAD of 10 years or longer, AEs were reported in 4.26%. AEs were reported in 4.64, 4.83, and 8.03% of CCS class I, class II, and class III and IV patients, respectively. AEs were reported in 6.91% of patients with a previous PCI and in 3.86% of patients without a PCI.

Discussion {#Sec7}
==========

This is the first study to assess the effectiveness of the metoprolol/ivabradine FDC in patient subgroups relevant to real-life clinical practice. We observed an additional reduction in HR, weekly angina attacks and SAN consumption at 4 months as well as a relevant improvement in the functional status of patients, with the proportion of patients in CCS class I (meaning asymptomatic at normal activity levels) increasing significantly versus baseline. Moreover, an improvement in self-reported medication adherence was reported with the use of the FDC. These beneficial effects were consistently found in all analyzed subgroups, regardless of age, CAD duration, comorbidities, previous MI, or history of revascularization.

The beneficial effects of combining ivabradine with a BB have been shown in several previously published studies with a similar design. The ASSOCIATE study \[[@CR11]\] showed that combining ivabradine with atenolol 50 mg led to an improvement in exercise tolerance test parameters. In the ADDITIONS study, in which more than 2000 patients were prospectively followed for 4 months, combining ivabradine with a BB in stable angina patients led to an additional reduction in HR, weekly angina attacks, and nitrate consumption \[[@CR12]\]. An observational, prospective, open-label study in 2403 Greek patients with chronic stable angina receiving ivabradine in combination with BBs showed antianginal effectiveness and improvement in quality of life (QoL) \[[@CR21]\].

The benefits of the ivabradine and BB combination have also been demonstrated in specific patient subpopulations, including the elderly, post-PCI patients, and patients with comorbidities. In elderly patients (≥ 80 years old) with stable angina, the 4-month, open-label, observational REDUCTION study \[[@CR22]\] reported a significant improvement in HR, angina attack frequency, and SAN consumption with ivabradine twice daily combined with a BB. A subgroup analysis of the ADDITIONS study in elderly patients (≥ 75 years old) also found that the addition of ivabradine to a BB effectively reduced HR, angina attacks, and nitrate consumption, and improved CCS symptom scores and QoL \[[@CR23]\]. The antianginal effectiveness of ivabradine administration in addition to a BB has also been shown in post hoc analyses of two observational studies in stable angina patients post-revascularization \[[@CR24], [@CR25]\]. A pooled analysis of eight multicenter, randomized, double-blind studies in patients with stable angina found similar reductions in HR and angina attack frequency both in patients with and without diabetes mellitus \[[@CR26]\]. A recent analysis of pooled data from three observational studies in 8555 stable angina patients receiving ivabradine 2.5 mg, 5 mg, or 7.5 mg twice daily for 4 months found a significant reduction in angina attack frequency and SAN consumption of 87% \[[@CR27]\]. Ivabradine was effective and safe in all subpopulations of angina patients seen in clinical practice, independent of age, comorbidities, and use of BBs.

In our study, the average dose of metoprolol was 78.4 mg and 86.1 mg at study entry and at 4 months, respectively, which is important in terms of the co-morbidity profile of most angina patients who cannot tolerate high doses of BB.

In a recent publication based on a Danish registry with more than 156,000 CAD patients, it was estimated that within a 10-year period, the average age had significantly increased by 2.1 years, reaching 63.9 years, with the burden of comorbidities also being significantly elevated \[[@CR28]\]. Consistent with these findings, in patients with stable angina included in the CLARIFY registry, the average age was 64 years and co-morbid conditions were frequent (hypertension was present in 71% of patients, lipid abnormalities in 75%, chronic renal disease in 22%, diabetes in 29%, heart failure in 15%, peripheral artery disease in 10%, and asthma/COPD in 7%) \[[@CR29]\]. This suggests that difficult-to-treat subpopulations of patients who are older and have more co-morbidities will be increasingly relevant to clinical practice. Our study suggests that the benefits of metoprolol/ivabradine treatment are also observed in these subpopulations.

In our analysis, we also found an improvement in self-reported medication adherence across all patient subgroups with the use of a FDC. At baseline, complete adherence was low, ranging from 25% to 40% of patients depending on the subgroup, while after 4 months of treatment with metoprolol/ivabradine complete adherence was observed in 44% to 66%, nearly doubling in some of the subgroups. One possible explanation for this increase in adherence could be the improvement in clinical status. Nevertheless, given the fact that the treatment was added to already-existing anti-anginal treatment and the initially low number of angina attacks and SAN consumption, we might speculate that the beneficial effect of metoprolol/ivabradine FDC was related to treatment simplification by combining two individual components of previously used anti-anginal therapy in a single-pill combination. Indeed, FDCs have been reported to improve adherence as compared to free combinations \[[@CR30], [@CR31]\]. As adherence declines with an increasing number of drugs, treatment simplification might be particularly relevant for patients taking several medications, as is often the case for elderly patients or those with co-morbidities, which were included in the subpopulations analyzed in the present study.

Study Limitations {#Sec8}
-----------------

The study has limitations inherent in the nature of its design (open-label, observational), which may have resulted in bias towards overestimating the treatment effect. Other limitations are the absence of a placebo group and assessment of adherence by the indirect method of patient self-reporting and at a relatively short follow-up period, which might have led to overestimation of the effect on adherence.

Conclusions {#Sec9}
===========

This prospective, multicenter, observational 4-month study found that treatment with the metoprolol/ivabradine FDC significantly reduced HR, decreased the frequency of angina attacks and SAN use, and improved patient functional status and medication adherence in patient subgroups relevant to real-life clinical practice.
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